1	Gen-Probe	_	NNP	_	_	8	SBJ	_	_
2	Inc.	_	NNP	_	_	1	POSTHON	_	_
3	,	_	,	_	_	1	P	_	_
4	a	_	DT	_	_	6	NMOD	_	_
5	biotechnology	_	NN	_	_	6	NMOD	_	_
6	concern	_	NN	_	_	1	APPO	_	_
7	,	_	,	_	_	1	P	_	_
8	said	_	VBD	_	_	0	ROOT	_	_
9	it	_	PRP	_	_	10	SBJ	_	_
10	signed	_	VBD	_	_	8	OBJ	_	_
11	a	_	DT	_	_	13	NMOD	_	_
12	definitive	_	JJ	_	_	13	NMOD	_	_
13	agreement	_	NN	_	_	10	OBJ	_	_
14	to	_	TO	_	_	13	NMOD	_	_
15	be	_	VB	_	_	14	IM	_	_
16	acquired	_	VBN	_	_	15	VC	_	_
17	by	_	IN	_	_	16	LGS	_	_
18	Chugai	_	NNP	_	_	19	NAME	_	_
19	Pharmaceutical	_	NNP	_	_	17	PMOD	_	_
20	Co.	_	NNP	_	_	19	POSTHON	_	_
21	of	_	IN	_	_	19	NMOD	_	_
22	Tokyo	_	NNP	_	_	21	PMOD	_	_
23	for	_	IN	_	_	16	ADV	_	_
24	about	_	RB	_	_	25	DEP	_	_
25	$	_	$	_	_	23	PMOD	_	_
26	110	_	CD	_	_	25	DEP	_	_
27	million	_	CD	_	_	25	DEP	_	_
28	,	_	,	_	_	25	P	_	_
29	or	_	CC	_	_	25	COORD	_	_
30	almost	_	RB	_	_	31	DEP	_	_
31	double	_	RB	_	_	34	NMOD	_	_
32	the	_	DT	_	_	34	NMOD	_	_
33	market	_	NN	_	_	34	NMOD	_	_
34	price	_	NN	_	_	29	CONJ	_	_
35	of	_	IN	_	_	34	NMOD	_	_
36	Gen-Probe	_	NNP	_	_	38	NMOD	_	_
37	's	_	POS	_	_	36	SUFFIX	_	_
38	stock	_	NN	_	_	35	PMOD	_	_
39	.	_	.	_	_	8	P	_	_

1	The	_	DT	_	_	2	NMOD	_	_
2	move	_	NN	_	_	3	SBJ	_	_
3	is	_	VBZ	_	_	0	ROOT	_	_
4	sure	_	JJ	_	_	3	PRD	_	_
5	to	_	TO	_	_	4	AMOD	_	_
6	heighten	_	VB	_	_	5	IM	_	_
7	concerns	_	NNS	_	_	6	OBJ	_	_
8	about	_	IN	_	_	7	NMOD	_	_
9	increased	_	VBN	_	_	11	NMOD	_	_
10	Japanese	_	JJ	_	_	11	NMOD	_	_
11	investment	_	NN	_	_	8	PMOD	_	_
12	in	_	IN	_	_	11	LOC	_	_
13	U.S.	_	NNP	_	_	15	NMOD	_	_
14	biotechnology	_	NN	_	_	15	NMOD	_	_
15	firms	_	NNS	_	_	12	PMOD	_	_
16	.	_	.	_	_	3	P	_	_

1	It	_	PRP	_	_	2	SBJ	_	_
2	is	_	VBZ	_	_	0	ROOT	_	_
3	also	_	RB	_	_	2	ADV	_	_
4	likely	_	JJ	_	_	2	PRD	_	_
5	to	_	TO	_	_	4	AMOD	_	_
6	bolster	_	VB	_	_	5	IM	_	_
7	fears	_	NNS	_	_	6	OBJ	_	_
8	that	_	IN	_	_	7	NMOD	_	_
9	the	_	DT	_	_	10	NMOD	_	_
10	Japanese	_	NNP	_	_	11	SBJ	_	_
11	will	_	MD	_	_	8	SUB	_	_
12	use	_	VB	_	_	11	VC	_	_
13	their	_	PRP$	_	_	14	NMOD	_	_
14	foothold	_	NN	_	_	12	OBJ	_	_
15	in	_	IN	_	_	14	LOC	_	_
16	U.S.	_	NNP	_	_	18	NMOD	_	_
17	biotechnology	_	NN	_	_	18	NMOD	_	_
18	concerns	_	NNS	_	_	15	PMOD	_	_
19	to	_	TO	_	_	12	OPRD	_	_
20	gain	_	VB	_	_	19	IM	_	_
21	certain	_	JJ	_	_	25	NMOD	_	_
22	trade	_	NN	_	_	25	NMOD	_	_
23	and	_	CC	_	_	22	COORD	_	_
24	competitive	_	JJ	_	_	23	CONJ	_	_
25	advantages	_	NNS	_	_	20	OBJ	_	_
26	.	_	.	_	_	2	P	_	_

1	Gen-Probe	_	NNP	_	_	25	SBJ	_	_
2	,	_	,	_	_	1	P	_	_
3	an	_	DT	_	_	5	NMOD	_	_
4	industry	_	NN	_	_	5	NMOD	_	_
5	leader	_	NN	_	_	1	APPO	_	_
6	in	_	IN	_	_	5	LOC	_	_
7	the	_	DT	_	_	8	NMOD	_	_
8	field	_	NN	_	_	6	PMOD	_	_
9	of	_	IN	_	_	8	NMOD	_	_
10	genetic	_	JJ	_	_	11	NMOD	_	_
11	probes	_	NNS	_	_	9	PMOD	_	_
12	,	_	,	_	_	11	P	_	_
13	which	_	WDT	_	_	14	SBJ	_	_
14	is	_	VBZ	_	_	11	NMOD	_	_
15	a	_	DT	_	_	17	NMOD	_	_
16	new	_	JJ	_	_	17	NMOD	_	_
17	technology	_	NN	_	_	14	PRD	_	_
18	used	_	VBN	_	_	17	APPO	_	_
19	in	_	IN	_	_	18	LOC	_	_
20	diagnostic	_	JJ	_	_	21	NMOD	_	_
21	tests	_	NNS	_	_	19	PMOD	_	_
22	,	_	,	_	_	1	P	_	_
23	last	_	JJ	_	_	24	NMOD	_	_
24	year	_	NN	_	_	25	TMP	_	_
25	signed	_	VBD	_	_	0	ROOT	_	_
26	an	_	DT	_	_	27	NMOD	_	_
27	agreement	_	NN	_	_	25	OBJ	_	_
28	for	_	IN	_	_	27	NMOD	_	_
29	Chugai	_	NNP	_	_	30	SBJ	_	_
30	to	_	TO	_	_	28	SUB	_	_
31	exclusively	_	RB	_	_	32	ADV	_	_
32	market	_	VB	_	_	30	IM	_	_
33	its	_	PRP$	_	_	35	NMOD	_	_
34	diagnostic	_	JJ	_	_	35	NMOD	_	_
35	products	_	NNS	_	_	32	OBJ	_	_
36	in	_	IN	_	_	32	LOC	_	_
37	Japan	_	NNP	_	_	36	PMOD	_	_
38	for	_	IN	_	_	35	NMOD	_	_
39	infectious	_	JJ	_	_	40	NMOD	_	_
40	diseases	_	NNS	_	_	38	PMOD	_	_
41	and	_	CC	_	_	40	COORD	_	_
42	cancer	_	NN	_	_	41	CONJ	_	_
43	.	_	.	_	_	25	P	_	_

1	Chugai	_	NNP	_	_	2	SBJ	_	_
2	agreed	_	VBD	_	_	0	ROOT	_	_
3	then	_	RB	_	_	2	TMP	_	_
4	to	_	TO	_	_	2	OPRD	_	_
5	fund	_	VB	_	_	4	IM	_	_
6	certain	_	JJ	_	_	8	NMOD	_	_
7	associated	_	VBN	_	_	8	NMOD	_	_
8	research	_	NN	_	_	5	OBJ	_	_
9	and	_	CC	_	_	8	COORD	_	_
10	development	_	NN	_	_	11	NMOD	_	_
11	costs	_	NNS	_	_	9	CONJ	_	_
12	.	_	.	_	_	2	P	_	_

1	That	_	DT	_	_	2	NMOD	_	_
2	arrangement	_	NN	_	_	4	SBJ	_	_
3	apparently	_	RB	_	_	4	ADV	_	_
4	has	_	VBZ	_	_	0	ROOT	_	_
5	worked	_	VBN	_	_	4	VC	_	_
6	well	_	RB	_	_	5	MNR	_	_
7	,	_	,	_	_	4	P	_	_
8	and	_	CC	_	_	4	COORD	_	_
9	Thomas	_	NNP	_	_	11	NAME	_	_
10	A.	_	NNP	_	_	11	NAME	_	_
11	Bologna	_	NNP	_	_	25	SBJ	_	_
12	,	_	,	_	_	11	P	_	_
13	president	_	NN	_	_	11	APPO	_	_
14	and	_	CC	_	_	13	COORD	_	_
15	chief	_	JJ	_	_	17	NMOD	_	_
16	executive	_	JJ	_	_	17	NMOD	_	_
17	officer	_	NN	_	_	14	CONJ	_	_
18	of	_	IN	_	_	13	NMOD	_	_
19	Gen-Probe	_	NNP	_	_	18	PMOD	_	_
20	,	_	,	_	_	19	P	_	_
21	founded	_	VBN	_	_	19	APPO	_	_
22	in	_	IN	_	_	21	TMP	_	_
23	1983	_	CD	_	_	22	PMOD	_	_
24	,	_	,	_	_	11	P	_	_
25	said	_	VBD	_	_	8	CONJ	_	_
26	the	_	DT	_	_	27	NMOD	_	_
27	sale	_	NN	_	_	31	SBJ	_	_
28	of	_	IN	_	_	27	NMOD	_	_
29	the	_	DT	_	_	30	NMOD	_	_
30	company	_	NN	_	_	28	PMOD	_	_
31	means	_	VBZ	_	_	25	OBJ	_	_
32	``	_	``	_	_	34	P	_	_
33	we	_	PRP	_	_	34	SBJ	_	_
34	will	_	MD	_	_	31	OBJ	_	_
35	be	_	VB	_	_	34	VC	_	_
36	able	_	JJ	_	_	35	PRD	_	_
37	to	_	TO	_	_	36	AMOD	_	_
38	concentrate	_	VB	_	_	37	IM	_	_
39	on	_	IN	_	_	38	ADV	_	_
40	running	_	VBG	_	_	39	PMOD	_	_
41	the	_	DT	_	_	42	NMOD	_	_
42	business	_	NN	_	_	40	OBJ	_	_
43	rather	_	RB	_	_	40	COORD	_	_
44	than	_	IN	_	_	43	DEP	_	_
45	always	_	RB	_	_	46	TMP	_	_
46	looking	_	VBG	_	_	43	CONJ	_	_
47	for	_	IN	_	_	46	ADV	_	_
48	sources	_	NNS	_	_	47	PMOD	_	_
49	of	_	IN	_	_	48	NMOD	_	_
50	financing	_	NN	_	_	49	PMOD	_	_
51	.	_	.	_	_	4	P	_	_
52	''	_	''	_	_	4	P	_	_

1	Chugai	_	NNP	_	_	2	SBJ	_	_
2	agreed	_	VBD	_	_	0	ROOT	_	_
3	to	_	TO	_	_	2	OPRD	_	_
4	pay	_	VB	_	_	3	IM	_	_
5	$	_	$	_	_	4	OBJ	_	_
6	6.25	_	CD	_	_	5	NMOD	_	_
7	a	_	DT	_	_	8	NMOD	_	_
8	share	_	NN	_	_	5	ADV	_	_
9	for	_	IN	_	_	4	ADV	_	_
10	Gen-Probe	_	NNP	_	_	15	NMOD	_	_
11	's	_	POS	_	_	10	SUFFIX	_	_
12	17.6	_	CD	_	_	13	DEP	_	_
13	million	_	CD	_	_	15	NMOD	_	_
14	common	_	JJ	_	_	15	NMOD	_	_
15	shares	_	NNS	_	_	9	PMOD	_	_
16	outstanding	_	JJ	_	_	15	APPO	_	_
17	on	_	IN	_	_	4	ADV	_	_
18	a	_	DT	_	_	21	NMOD	_	_
19	fully	_	RB	_	_	20	AMOD	_	_
20	diluted	_	VBN	_	_	21	NMOD	_	_
21	basis	_	NN	_	_	17	PMOD	_	_
22	.	_	.	_	_	2	P	_	_

1	Yesterday	_	NN	_	_	13	TMP	_	_
2	,	_	,	_	_	13	P	_	_
3	in	_	IN	_	_	13	LOC	_	_
4	national	_	JJ	_	_	5	NMOD	_	_
5	trading	_	NN	_	_	3	PMOD	_	_
6	in	_	IN	_	_	5	LOC	_	_
7	the	_	DT	_	_	9	NMOD	_	_
8	over-the-counter	_	JJ	_	_	9	NMOD	_	_
9	market	_	NN	_	_	6	PMOD	_	_
10	,	_	,	_	_	13	P	_	_
11	Gen-Probe	_	NNP	_	_	12	NMOD	_	_
12	common	_	NN	_	_	13	SBJ	_	_
13	closed	_	VBD	_	_	0	ROOT	_	_
14	at	_	IN	_	_	13	ADV	_	_
15	$	_	$	_	_	14	PMOD	_	_
16	3.25	_	CD	_	_	15	NMOD	_	_
17	a	_	DT	_	_	18	NMOD	_	_
18	share	_	NN	_	_	15	ADV	_	_
19	.	_	.	_	_	13	P	_	_

1	Because	_	IN	_	_	23	PRP	_	_
2	the	_	DT	_	_	3	NMOD	_	_
3	U.S.	_	NNP	_	_	4	SBJ	_	_
4	leads	_	VBZ	_	_	1	SUB	_	_
5	in	_	IN	_	_	4	ADV	_	_
6	most	_	JJS	_	_	7	NMOD	_	_
7	areas	_	NNS	_	_	5	PMOD	_	_
8	of	_	IN	_	_	7	NMOD	_	_
9	biotechnology	_	NN	_	_	8	PMOD	_	_
10	--	_	:	_	_	4	P	_	_
11	largely	_	RB	_	_	12	PMOD	_	_
12	because	_	IN	_	_	4	PRP	_	_
13	of	_	IN	_	_	12	DEP	_	_
14	research	_	NN	_	_	15	NMOD	_	_
15	investment	_	NN	_	_	12	PMOD	_	_
16	by	_	IN	_	_	15	LGS	_	_
17	the	_	DT	_	_	19	NMOD	_	_
18	U.S.	_	NNP	_	_	19	NMOD	_	_
19	government	_	NN	_	_	16	PMOD	_	_
20	--	_	:	_	_	4	P	_	_
21	the	_	DT	_	_	22	NMOD	_	_
22	sale	_	NN	_	_	23	SBJ	_	_
23	is	_	VBZ	_	_	0	ROOT	_	_
24	sure	_	JJ	_	_	23	PRD	_	_
25	to	_	TO	_	_	24	AMOD	_	_
26	increase	_	VB	_	_	25	IM	_	_
27	concerns	_	NNS	_	_	26	OBJ	_	_
28	that	_	IN	_	_	27	NMOD	_	_
29	Japanese	_	JJ	_	_	30	NMOD	_	_
30	companies	_	NNS	_	_	31	SBJ	_	_
31	will	_	MD	_	_	28	SUB	_	_
32	buy	_	VB	_	_	31	VC	_	_
33	American	_	NNP	_	_	34	NMOD	_	_
34	know-how	_	NN	_	_	32	OBJ	_	_
35	and	_	CC	_	_	32	COORD	_	_
36	use	_	VB	_	_	35	CONJ	_	_
37	it	_	PRP	_	_	36	OBJ	_	_
38	to	_	TO	_	_	36	OPRD	_	_
39	obtain	_	VB	_	_	38	IM	_	_
40	the	_	DT	_	_	42	NMOD	_	_
41	upper	_	JJ	_	_	42	NMOD	_	_
42	hand	_	NN	_	_	39	OBJ	_	_
43	in	_	IN	_	_	39	LOC	_	_
44	biotechnology	_	NN	_	_	45	NMOD	_	_
45	trade	_	NN	_	_	43	PMOD	_	_
46	and	_	CC	_	_	45	COORD	_	_
47	competition	_	NN	_	_	46	CONJ	_	_
48	.	_	.	_	_	23	P	_	_

1	``	_	``	_	_	14	P	_	_
2	The	_	DT	_	_	4	NMOD	_	_
3	biotechnology	_	NN	_	_	4	NMOD	_	_
4	firms	_	NNS	_	_	5	SBJ	_	_
5	may	_	MD	_	_	14	OBJ	_	_
6	be	_	VB	_	_	5	VC	_	_
7	setting	_	VBG	_	_	6	VC	_	_
8	up	_	RP	_	_	7	PRT	_	_
9	their	_	PRP$	_	_	11	NMOD	_	_
10	own	_	JJ	_	_	11	NMOD	_	_
11	competitors	_	NNS	_	_	7	OBJ	_	_
12	,	_	,	_	_	14	P	_	_
13	''	_	''	_	_	14	P	_	_
14	said	_	VBD	_	_	0	ROOT	_	_
15	Richard	_	NNP	_	_	16	NAME	_	_
16	Godown	_	NNP	_	_	14	SBJ	_	_
17	,	_	,	_	_	16	P	_	_
18	president	_	NN	_	_	16	APPO	_	_
19	of	_	IN	_	_	18	NMOD	_	_
20	the	_	DT	_	_	23	NMOD	_	_
21	Industrial	_	NNP	_	_	23	NAME	_	_
22	Biotechnology	_	NNP	_	_	23	NAME	_	_
23	Association	_	NNP	_	_	19	PMOD	_	_
24	.	_	.	_	_	14	P	_	_

1	He	_	PRP	_	_	2	SBJ	_	_
2	added	_	VBD	_	_	0	ROOT	_	_
3	that	_	IN	_	_	2	OBJ	_	_
4	until	_	IN	_	_	8	TMP	_	_
5	now	_	RB	_	_	4	PMOD	_	_
6	the	_	DT	_	_	7	NMOD	_	_
7	Japanese	_	NNS	_	_	8	SBJ	_	_
8	have	_	VBP	_	_	3	SUB	_	_
9	only	_	RB	_	_	10	ADV	_	_
10	acquired	_	VBN	_	_	8	VC	_	_
11	equity	_	NN	_	_	12	NMOD	_	_
12	positions	_	NNS	_	_	10	OBJ	_	_
13	in	_	IN	_	_	12	LOC	_	_
14	U.S.	_	NNP	_	_	16	NMOD	_	_
15	biotechnology	_	NN	_	_	16	NMOD	_	_
16	companies	_	NNS	_	_	13	PMOD	_	_
17	.	_	.	_	_	2	P	_	_

1	``	_	``	_	_	11	P	_	_
2	They	_	PRP	_	_	3	SBJ	_	_
3	are	_	VBP	_	_	11	OBJ	_	_
4	piggybacking	_	VBG	_	_	3	VC	_	_
5	onto	_	IN	_	_	4	ADV	_	_
6	developed	_	VBN	_	_	7	NMOD	_	_
7	technology	_	NN	_	_	5	PMOD	_	_
8	,	_	,	_	_	11	P	_	_
9	''	_	''	_	_	11	P	_	_
10	he	_	PRP	_	_	11	SBJ	_	_
11	said	_	VBD	_	_	0	ROOT	_	_
12	.	_	.	_	_	11	P	_	_

1	During	_	IN	_	_	9	TMP	_	_
2	the	_	DT	_	_	5	NMOD	_	_
3	past	_	JJ	_	_	5	NMOD	_	_
4	five	_	CD	_	_	5	NMOD	_	_
5	years	_	NNS	_	_	1	PMOD	_	_
6	,	_	,	_	_	9	P	_	_
7	Japanese	_	JJ	_	_	8	NMOD	_	_
8	concerns	_	NNS	_	_	9	SBJ	_	_
9	have	_	VBP	_	_	0	ROOT	_	_
10	invested	_	VBN	_	_	9	VC	_	_
11	in	_	IN	_	_	10	ADV	_	_
12	several	_	JJ	_	_	11	PMOD	_	_
13	of	_	IN	_	_	12	NMOD	_	_
14	the	_	DT	_	_	15	NMOD	_	_
15	U.S.	_	NNP	_	_	20	NMOD	_	_
16	's	_	POS	_	_	15	SUFFIX	_	_
17	431	_	CD	_	_	20	NMOD	_	_
18	independent	_	JJ	_	_	20	NMOD	_	_
19	biotechnology	_	NN	_	_	20	NMOD	_	_
20	companies	_	NNS	_	_	13	PMOD	_	_
21	.	_	.	_	_	9	P	_	_

1	Chugai	_	NNP	_	_	2	SBJ	_	_
2	has	_	VBZ	_	_	0	ROOT	_	_
3	been	_	VBN	_	_	2	VC	_	_
4	one	_	CD	_	_	3	PRD	_	_
5	of	_	IN	_	_	4	NMOD	_	_
6	the	_	DT	_	_	10	NMOD	_	_
7	most	_	RBS	_	_	8	AMOD	_	_
8	active	_	JJ	_	_	10	NMOD	_	_
9	Japanese	_	JJ	_	_	10	NMOD	_	_
10	players	_	NNS	_	_	5	PMOD	_	_
11	in	_	IN	_	_	10	LOC	_	_
12	U.S.	_	NNP	_	_	14	NMOD	_	_
13	biotechnology	_	NN	_	_	14	NMOD	_	_
14	companies	_	NNS	_	_	11	PMOD	_	_
15	;	_	:	_	_	2	P	_	_
16	it	_	PRP	_	_	17	SBJ	_	_
17	has	_	VBZ	_	_	2	COORD	_	_
18	an	_	DT	_	_	20	NMOD	_	_
19	equity	_	NN	_	_	20	NMOD	_	_
20	investment	_	NN	_	_	17	OBJ	_	_
21	in	_	IN	_	_	20	LOC	_	_
22	Genetics	_	NNP	_	_	23	NAME	_	_
23	Institute	_	NNP	_	_	21	PMOD	_	_
24	Inc.	_	NNP	_	_	23	POSTHON	_	_
25	,	_	,	_	_	23	P	_	_
26	Cambridge	_	NNP	_	_	23	LOC	_	_
27	,	_	,	_	_	26	P	_	_
28	Mass.	_	NNP	_	_	26	APPO	_	_
29	,	_	,	_	_	26	P	_	_
30	and	_	CC	_	_	20	COORD	_	_
31	a	_	DT	_	_	33	NMOD	_	_
32	joint-venture	_	JJ	_	_	33	NMOD	_	_
33	agreement	_	NN	_	_	30	CONJ	_	_
34	with	_	IN	_	_	33	NMOD	_	_
35	Upjohn	_	NNP	_	_	34	PMOD	_	_
36	Co.	_	NNP	_	_	35	POSTHON	_	_
37	,	_	,	_	_	35	P	_	_
38	Kalamazoo	_	NNP	_	_	35	LOC	_	_
39	,	_	,	_	_	38	P	_	_
40	Mich	_	NNP	_	_	38	APPO	_	_
41	.	_	.	_	_	2	P	_	_

1	The	_	DT	_	_	3	NMOD	_	_
2	Japanese	_	JJ	_	_	3	NMOD	_	_
3	government	_	NN	_	_	9	SBJ	_	_
4	,	_	,	_	_	7	P	_	_
5	Mr.	_	NNP	_	_	6	TITLE	_	_
6	Godown	_	NNP	_	_	7	SBJ	_	_
7	said	_	VBD	_	_	0	ROOT	_	_
8	,	_	,	_	_	7	P	_	_
9	has	_	VBZ	_	_	7	OBJ	_	_
10	stated	_	VBN	_	_	9	VC	_	_
11	that	_	IN	_	_	10	OBJ	_	_
12	it	_	PRP	_	_	13	SBJ	_	_
13	wants	_	VBZ	_	_	11	SUB	_	_
14	10	_	CD	_	_	18	DEP	_	_
15	%	_	NN	_	_	18	DEP	_	_
16	to	_	TO	_	_	18	DEP	_	_
17	11	_	CD	_	_	18	DEP	_	_
18	%	_	NN	_	_	13	OBJ	_	_
19	of	_	IN	_	_	18	NMOD	_	_
20	its	_	PRP$	_	_	23	NMOD	_	_
21	gross	_	JJ	_	_	23	NMOD	_	_
22	national	_	JJ	_	_	23	NMOD	_	_
23	product	_	NN	_	_	19	PMOD	_	_
24	to	_	TO	_	_	13	OPRD	_	_
25	come	_	VB	_	_	24	IM	_	_
26	from	_	IN	_	_	25	ADV	_	_
27	biotechnology	_	NN	_	_	28	NMOD	_	_
28	products	_	NNS	_	_	26	PMOD	_	_
29	.	_	.	_	_	9	P	_	_

1	``	_	``	_	_	20	P	_	_
2	It	_	PRP	_	_	3	SBJ	_	_
3	is	_	VBZ	_	_	20	OBJ	_	_
4	becoming	_	VBG	_	_	3	VC	_	_
5	more	_	JJR	_	_	4	PRD	_	_
6	of	_	IN	_	_	5	NMOD	_	_
7	a	_	DT	_	_	9	NMOD	_	_
8	horse	_	NN	_	_	9	NMOD	_	_
9	race	_	NN	_	_	6	PMOD	_	_
10	every	_	DT	_	_	11	NMOD	_	_
11	day	_	NN	_	_	4	TMP	_	_
12	between	_	IN	_	_	9	NMOD	_	_
13	the	_	DT	_	_	14	NMOD	_	_
14	U.S.	_	NNP	_	_	12	PMOD	_	_
15	and	_	CC	_	_	14	COORD	_	_
16	Japan	_	NNP	_	_	15	CONJ	_	_
17	,	_	,	_	_	20	P	_	_
18	''	_	''	_	_	20	P	_	_
19	he	_	PRP	_	_	20	SBJ	_	_
20	said	_	VBD	_	_	0	ROOT	_	_
21	,	_	,	_	_	20	P	_	_
22	adding	_	VBG	_	_	20	ADV	_	_
23	that	_	IN	_	_	22	OBJ	_	_
24	some	_	DT	_	_	25	SBJ	_	_
25	fear	_	VBP	_	_	23	SUB	_	_
26	that	_	IN	_	_	25	OBJ	_	_
27	as	_	IN	_	_	40	ADV	_	_
28	with	_	IN	_	_	27	PMOD	_	_
29	the	_	DT	_	_	30	NMOD	_	_
30	semiconductor	_	NN	_	_	28	PMOD	_	_
31	,	_	,	_	_	30	P	_	_
32	electronics	_	NNS	_	_	30	COORD	_	_
33	,	_	,	_	_	32	P	_	_
34	and	_	CC	_	_	32	COORD	_	_
35	automobile	_	NN	_	_	36	NMOD	_	_
36	industries	_	NNS	_	_	34	CONJ	_	_
37	,	_	,	_	_	40	P	_	_
38	Japanese	_	JJ	_	_	39	NMOD	_	_
39	companies	_	NNS	_	_	40	SBJ	_	_
40	will	_	MD	_	_	26	SUB	_	_
41	use	_	VB	_	_	40	VC	_	_
42	U.S.-developed	_	JJ	_	_	43	NMOD	_	_
43	technology	_	NN	_	_	41	OBJ	_	_
44	to	_	TO	_	_	41	OPRD	_	_
45	gain	_	VB	_	_	44	IM	_	_
46	trade	_	NN	_	_	47	NMOD	_	_
47	advantages	_	NNS	_	_	45	OBJ	_	_
48	.	_	.	_	_	20	P	_	_

1	Mr.	_	NNP	_	_	2	TITLE	_	_
2	Bologna	_	NNP	_	_	3	SBJ	_	_
3	said	_	VBD	_	_	0	ROOT	_	_
4	the	_	DT	_	_	5	NMOD	_	_
5	sale	_	NN	_	_	6	SBJ	_	_
6	would	_	MD	_	_	3	OBJ	_	_
7	allow	_	VB	_	_	6	VC	_	_
8	Gen-Probe	_	NNP	_	_	7	OBJ	_	_
9	to	_	TO	_	_	7	OPRD	_	_
10	speed	_	VB	_	_	9	IM	_	_
11	up	_	RP	_	_	10	PRT	_	_
12	the	_	DT	_	_	13	NMOD	_	_
13	development	_	NN	_	_	10	OBJ	_	_
14	of	_	IN	_	_	13	NMOD	_	_
15	new	_	JJ	_	_	16	NMOD	_	_
16	technology	_	NN	_	_	14	PMOD	_	_
17	,	_	,	_	_	9	P	_	_
18	and	_	CC	_	_	9	COORD	_	_
19	to	_	TO	_	_	18	CONJ	_	_
20	more	_	RBR	_	_	21	AMOD	_	_
21	quickly	_	RB	_	_	19	MNR	_	_
22	apply	_	VB	_	_	19	IM	_	_
23	existing	_	VBG	_	_	24	NMOD	_	_
24	technology	_	NN	_	_	22	OBJ	_	_
25	to	_	TO	_	_	22	ADV	_	_
26	an	_	DT	_	_	27	NMOD	_	_
27	array	_	NN	_	_	25	PMOD	_	_
28	of	_	IN	_	_	27	NMOD	_	_
29	diagnostic	_	JJ	_	_	30	NMOD	_	_
30	products	_	NNS	_	_	28	PMOD	_	_
31	the	_	DT	_	_	32	NMOD	_	_
32	company	_	NN	_	_	33	SBJ	_	_
33	wants	_	VBZ	_	_	30	NMOD	_	_
34	to	_	TO	_	_	33	OPRD	_	_
35	offer	_	VB	_	_	34	IM	_	_
36	.	_	.	_	_	3	P	_	_

1	By	_	IN	_	_	31	TMP	_	_
2	1988	_	CD	_	_	1	PMOD	_	_
3	,	_	,	_	_	2	P	_	_
4	when	_	WRB	_	_	18	TMP	_	_
5	only	_	RB	_	_	9	NMOD	_	_
6	10	_	CD	_	_	5	DEP	_	_
7	genetic	_	JJ	_	_	9	NMOD	_	_
8	probe-based	_	JJ	_	_	9	NMOD	_	_
9	tests	_	NNS	_	_	16	SBJ	_	_
10	of	_	IN	_	_	9	NMOD	_	_
11	diagnostic	_	JJ	_	_	13	NMOD	_	_
12	infectious	_	JJ	_	_	13	NMOD	_	_
13	diseases	_	NNS	_	_	10	PMOD	_	_
14	of	_	IN	_	_	13	NMOD	_	_
15	humans	_	NNS	_	_	14	PMOD	_	_
16	had	_	VBD	_	_	2	NMOD	_	_
17	been	_	VBN	_	_	16	VC	_	_
18	approved	_	VBN	_	_	17	VC	_	_
19	for	_	IN	_	_	18	PRP	_	_
20	marketing	_	VBG	_	_	19	PMOD	_	_
21	by	_	IN	_	_	18	LGS	_	_
22	the	_	DT	_	_	23	NMOD	_	_
23	Food	_	NNP	_	_	21	PMOD	_	_
24	and	_	CC	_	_	23	COORD	_	_
25	Drug	_	NNP	_	_	26	NAME	_	_
26	Administration	_	NNP	_	_	24	CONJ	_	_
27	,	_	,	_	_	31	P	_	_
28	eight	_	CD	_	_	31	SBJ	_	_
29	of	_	IN	_	_	28	NMOD	_	_
30	them	_	PRP	_	_	29	PMOD	_	_
31	had	_	VBD	_	_	0	ROOT	_	_
32	been	_	VBN	_	_	31	VC	_	_
33	developed	_	VBN	_	_	32	VC	_	_
34	and	_	CC	_	_	33	COORD	_	_
35	sold	_	VBN	_	_	34	CONJ	_	_
36	by	_	IN	_	_	33	LGS	_	_
37	Gen-Probe	_	NNP	_	_	36	PMOD	_	_
38	.	_	.	_	_	31	P	_	_

1	Osamu	_	NNP	_	_	2	NAME	_	_
2	Nagayama	_	NNP	_	_	22	SBJ	_	_
3	,	_	,	_	_	2	P	_	_
4	deputy	_	NN	_	_	5	NMOD	_	_
5	president	_	NN	_	_	2	APPO	_	_
6	of	_	IN	_	_	5	NMOD	_	_
7	Chugai	_	NNP	_	_	6	PMOD	_	_
8	,	_	,	_	_	7	P	_	_
9	which	_	WDT	_	_	10	SBJ	_	_
10	spends	_	VBZ	_	_	7	NMOD	_	_
11	about	_	RB	_	_	13	NMOD	_	_
12	15	_	CD	_	_	11	DEP	_	_
13	%	_	NN	_	_	10	OBJ	_	_
14	of	_	IN	_	_	13	NMOD	_	_
15	its	_	PRP$	_	_	16	NMOD	_	_
16	sales	_	NNS	_	_	14	PMOD	_	_
17	on	_	IN	_	_	10	ADV	_	_
18	research	_	NN	_	_	17	PMOD	_	_
19	and	_	CC	_	_	18	COORD	_	_
20	development	_	NN	_	_	19	CONJ	_	_
21	,	_	,	_	_	2	P	_	_
22	was	_	VBD	_	_	0	ROOT	_	_
23	unable	_	JJ	_	_	22	PRD	_	_
24	to	_	TO	_	_	23	AMOD	_	_
25	pinpoint	_	VB	_	_	24	IM	_	_
26	how	_	WRB	_	_	28	NMOD	_	_
27	much	_	JJ	_	_	26	AMOD	_	_
28	money	_	NN	_	_	31	OBJ	_	_
29	Chugai	_	NNP	_	_	30	SBJ	_	_
30	would	_	MD	_	_	25	OBJ	_	_
31	pump	_	VB	_	_	30	VC	_	_
32	into	_	IN	_	_	31	ADV	_	_
33	Gen-Probe	_	NNP	_	_	32	PMOD	_	_
34	.	_	.	_	_	22	P	_	_

1	``	_	``	_	_	15	P	_	_
2	We	_	PRP	_	_	3	SBJ	_	_
3	think	_	VBP	_	_	15	OBJ	_	_
4	Gen-Probe	_	NNP	_	_	5	SBJ	_	_
5	has	_	VBZ	_	_	3	OBJ	_	_
6	technology	_	NN	_	_	5	OBJ	_	_
7	important	_	JJ	_	_	6	APPO	_	_
8	to	_	TO	_	_	7	AMOD	_	_
9	people	_	NNS	_	_	11	NMOD	_	_
10	's	_	POS	_	_	9	SUFFIX	_	_
11	health	_	NN	_	_	8	PMOD	_	_
12	,	_	,	_	_	15	P	_	_
13	''	_	''	_	_	15	P	_	_
14	he	_	PRP	_	_	15	SBJ	_	_
15	said	_	VBD	_	_	0	ROOT	_	_
16	,	_	,	_	_	15	P	_	_
17	adding	_	VBG	_	_	15	ADV	_	_
18	:	_	:	_	_	17	P	_	_
19	``	_	``	_	_	17	P	_	_
20	We	_	PRP	_	_	21	SBJ	_	_
21	think	_	VBP	_	_	17	OBJ	_	_
22	it	_	PRP	_	_	23	SBJ	_	_
23	is	_	VBZ	_	_	21	OBJ	_	_
24	important	_	JJ	_	_	23	PRD	_	_
25	for	_	IN	_	_	23	EXTR	_	_
26	us	_	PRP	_	_	27	SBJ	_	_
27	to	_	TO	_	_	25	SUB	_	_
28	have	_	VB	_	_	27	IM	_	_
29	such	_	JJ	_	_	30	NMOD	_	_
30	technology	_	NN	_	_	28	OBJ	_	_
31	.	_	.	_	_	15	P	_	_
32	''	_	''	_	_	15	P	_	_

1	He	_	PRP	_	_	5	SBJ	_	_
2	and	_	CC	_	_	1	COORD	_	_
3	Mr.	_	NNP	_	_	4	TITLE	_	_
4	Bologna	_	NNP	_	_	2	CONJ	_	_
5	emphasized	_	VBD	_	_	0	ROOT	_	_
6	that	_	IN	_	_	5	OBJ	_	_
7	both	_	DT	_	_	8	NMOD	_	_
8	companies	_	NNS	_	_	9	SBJ	_	_
9	would	_	MD	_	_	6	SUB	_	_
10	gain	_	VB	_	_	9	VC	_	_
11	technological	_	JJ	_	_	12	NMOD	_	_
12	knowledge	_	NN	_	_	10	OBJ	_	_
13	through	_	IN	_	_	10	MNR	_	_
14	the	_	DT	_	_	15	NMOD	_	_
15	sale	_	NN	_	_	13	PMOD	_	_
16	of	_	IN	_	_	15	NMOD	_	_
17	Gen-Probe	_	NNP	_	_	16	PMOD	_	_
18	,	_	,	_	_	17	P	_	_
19	which	_	WDT	_	_	20	SBJ	_	_
20	will	_	MD	_	_	17	NMOD	_	_
21	expand	_	VB	_	_	20	VC	_	_
22	``	_	``	_	_	21	P	_	_
23	significantly	_	RB	_	_	21	ADV	_	_
24	''	_	''	_	_	21	P	_	_
25	as	_	IN	_	_	21	ADV	_	_
26	a	_	DT	_	_	27	NMOD	_	_
27	result	_	NN	_	_	25	PMOD	_	_
28	of	_	IN	_	_	27	NMOD	_	_
29	the	_	DT	_	_	30	NMOD	_	_
30	acquisition	_	NN	_	_	28	PMOD	_	_
31	.	_	.	_	_	5	P	_	_

1	In	_	IN	_	_	5	TMP	_	_
2	1988	_	CD	_	_	1	PMOD	_	_
3	,	_	,	_	_	5	P	_	_
4	Chugai	_	NNP	_	_	5	SBJ	_	_
5	had	_	VBD	_	_	0	ROOT	_	_
6	net	_	JJ	_	_	7	NMOD	_	_
7	income	_	NN	_	_	5	OBJ	_	_
8	of	_	IN	_	_	7	NMOD	_	_
9	$	_	$	_	_	8	PMOD	_	_
10	60	_	CD	_	_	9	DEP	_	_
11	million	_	CD	_	_	9	DEP	_	_
12	on	_	IN	_	_	5	ADV	_	_
13	revenue	_	NN	_	_	12	PMOD	_	_
14	of	_	IN	_	_	13	NMOD	_	_
15	$	_	$	_	_	14	PMOD	_	_
16	991	_	CD	_	_	15	DEP	_	_
17	million	_	CD	_	_	15	DEP	_	_
18	.	_	.	_	_	5	P	_	_

1	GenProbe	_	NN	_	_	2	SBJ	_	_
2	had	_	VBD	_	_	0	ROOT	_	_
3	a	_	DT	_	_	5	NMOD	_	_
4	net	_	JJ	_	_	5	NMOD	_	_
5	loss	_	NN	_	_	2	OBJ	_	_
6	of	_	IN	_	_	5	NMOD	_	_
7	$	_	$	_	_	6	PMOD	_	_
8	9.5	_	CD	_	_	7	DEP	_	_
9	million	_	CD	_	_	7	DEP	_	_
10	on	_	IN	_	_	2	ADV	_	_
11	revenue	_	NN	_	_	10	PMOD	_	_
12	of	_	IN	_	_	11	NMOD	_	_
13	$	_	$	_	_	12	PMOD	_	_
14	5.8	_	CD	_	_	13	NMOD	_	_
15	million	_	CD	_	_	13	NMOD	_	_
16	.	_	.	_	_	2	P	_	_

1	Recently	_	RB	_	_	4	TMP	_	_
2	,	_	,	_	_	4	P	_	_
3	Gen-Probe	_	NNP	_	_	4	SBJ	_	_
4	received	_	VBD	_	_	0	ROOT	_	_
5	a	_	DT	_	_	8	NMOD	_	_
6	broad	_	JJ	_	_	8	NMOD	_	_
7	U.S.	_	NNP	_	_	8	NMOD	_	_
8	patent	_	NN	_	_	4	OBJ	_	_
9	for	_	IN	_	_	8	NMOD	_	_
10	a	_	DT	_	_	11	NMOD	_	_
11	technology	_	NN	_	_	9	PMOD	_	_
12	that	_	WDT	_	_	13	SBJ	_	_
13	helps	_	VBZ	_	_	11	NMOD	_	_
14	detect	_	VB	_	_	13	VC	_	_
15	,	_	,	_	_	14	P	_	_
16	identify	_	VB	_	_	14	COORD	_	_
17	and	_	CC	_	_	16	COORD	_	_
18	quantify	_	VB	_	_	17	CONJ	_	_
19	non-viral	_	JJ	_	_	20	NMOD	_	_
20	organisms	_	NNS	_	_	14	OBJ	_	_
21	through	_	IN	_	_	14	MNR	_	_
22	the	_	DT	_	_	23	NMOD	_	_
23	targeting	_	VBG	_	_	21	PMOD	_	_
24	of	_	IN	_	_	23	NMOD	_	_
25	a	_	DT	_	_	26	NMOD	_	_
26	form	_	NN	_	_	24	PMOD	_	_
27	of	_	IN	_	_	26	NMOD	_	_
28	genetic	_	JJ	_	_	29	NMOD	_	_
29	material	_	NN	_	_	27	PMOD	_	_
30	called	_	VBN	_	_	29	APPO	_	_
31	ribosomal	_	JJ	_	_	32	NMOD	_	_
32	RNA	_	NNP	_	_	30	OPRD	_	_
33	.	_	.	_	_	4	P	_	_

1	Among	_	IN	_	_	7	ADV	_	_
2	other	_	JJ	_	_	3	NMOD	_	_
3	things	_	NNS	_	_	1	PMOD	_	_
4	,	_	,	_	_	7	P	_	_
5	Mr.	_	NNP	_	_	6	TITLE	_	_
6	Bologna	_	NNP	_	_	7	SBJ	_	_
7	said	_	VBD	_	_	0	ROOT	_	_
8	that	_	IN	_	_	7	OBJ	_	_
9	the	_	DT	_	_	10	NMOD	_	_
10	sale	_	NN	_	_	11	SBJ	_	_
11	will	_	MD	_	_	8	SUB	_	_
12	facilitate	_	VB	_	_	11	VC	_	_
13	Gen-Probe	_	NNP	_	_	15	NMOD	_	_
14	's	_	POS	_	_	13	SUFFIX	_	_
15	marketing	_	NN	_	_	12	OBJ	_	_
16	of	_	IN	_	_	15	NMOD	_	_
17	a	_	DT	_	_	19	NMOD	_	_
18	diagnostic	_	JJ	_	_	19	NMOD	_	_
19	test	_	NN	_	_	16	PMOD	_	_
20	for	_	IN	_	_	19	NMOD	_	_
21	acquired	_	VBN	_	_	24	NMOD	_	_
22	immune	_	JJ	_	_	24	NMOD	_	_
23	deficiency	_	NN	_	_	24	NMOD	_	_
24	syndrome	_	NN	_	_	20	PMOD	_	_
25	,	_	,	_	_	24	P	_	_
26	or	_	CC	_	_	24	COORD	_	_
27	AIDS	_	NNP	_	_	26	CONJ	_	_
28	.	_	.	_	_	7	P	_	_

1	Chugai	_	NNP	_	_	3	SBJ	_	_
2	also	_	RB	_	_	3	ADV	_	_
3	will	_	MD	_	_	17	OBJ	_	_
4	help	_	VB	_	_	3	VC	_	_
5	Gen-Probe	_	NNP	_	_	4	OBJ	_	_
6	with	_	IN	_	_	4	MNR	_	_
7	its	_	PRP$	_	_	11	NMOD	_	_
8	regulatory	_	JJ	_	_	11	NMOD	_	_
9	and	_	CC	_	_	8	COORD	_	_
10	marketing	_	NN	_	_	9	CONJ	_	_
11	expertise	_	NN	_	_	6	PMOD	_	_
12	in	_	IN	_	_	11	LOC	_	_
13	Asia	_	NNP	_	_	12	PMOD	_	_
14	,	_	,	_	_	17	P	_	_
15	Mr.	_	NNP	_	_	16	TITLE	_	_
16	Bologna	_	NNP	_	_	17	SBJ	_	_
17	said	_	VBD	_	_	0	ROOT	_	_
18	.	_	.	_	_	17	P	_	_

1	The	_	DT	_	_	3	NMOD	_	_
2	tender	_	NN	_	_	3	NMOD	_	_
3	offer	_	NN	_	_	8	SBJ	_	_
4	for	_	IN	_	_	3	NMOD	_	_
5	Gen-Probe	_	NNP	_	_	7	NMOD	_	_
6	's	_	POS	_	_	5	SUFFIX	_	_
7	shares	_	NNS	_	_	4	PMOD	_	_
8	is	_	VBZ	_	_	17	OBJ	_	_
9	expected	_	VBN	_	_	8	VC	_	_
10	to	_	TO	_	_	9	OPRD	_	_
11	begin	_	VB	_	_	10	IM	_	_
12	next	_	JJ	_	_	13	NMOD	_	_
13	Monday	_	NNP	_	_	11	TMP	_	_
14	,	_	,	_	_	17	P	_	_
15	the	_	DT	_	_	16	NMOD	_	_
16	company	_	NN	_	_	17	SBJ	_	_
17	said	_	VBD	_	_	0	ROOT	_	_
18	.	_	.	_	_	17	P	_	_

